Arix IPO raises £100M for new biotech investments; Santhera sets up shop in Massachusetts

• As expected, the UK’s Arix Biosciences has raised £100 million in its IPO, which will now fuel a new round of investments in biotech companies. “We have a highly experienced international team and this new capital enables us to continue our commitment to supporting businesses in the vanguard of medical innovation, with the ultimate goal of improving outcomes for patients and unlocking value for investors,” said CEO Joe Anderson.

• Switzerland’s Santhera has opened up shop in Massachusetts. The new facility, reports the Boston Business Journal, will start off with a staff of about 20 under the guidance of Tom Bazemore.

• Takeda and TiGenix NV {$TIG) announced new Phase III data from their ADMIRE-CD clinical trial, which “indicated that investigational compound Cx601, a suspension of allogeneic expanded adipose-derived stem cells (eASC), maintained long-term remission of treatment refractory complex perianal fistulas in patients with Crohn’s disease over 52 weeks.”

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy